Comprehensive Cancer Center Program at Fox Chase

项目摘要/摘要--总体 狐狸大通癌症中心，作为NCI指定的综合癌症，现已进入第51个年头 自上次CCSG赠款审查以来，该中心经历了深刻的变化。2012年，福克斯 Chase与天普大学健康系统建立了联系，创造了一种独特的新模式， 结合了独立癌症中心的灵活性和大学的科学和临床广度- 基于矩阵中心。除了这一组织变化外，2013年，fccc还接受了新的领导， 任命Richard I.Fisher医学博士为fccc总裁兼首席执行官兼癌症中心主任。作为一名 由于这些发展，癌症中心的规模和范围大大扩大，在以下两方面 它的科学事业，以及所服务的患者的数量和多样性。专注于癌症，坦普尔 教职员工已被彻底整合到PCC，增加了54名新的CCSG成员，其中包括3名 领导职位(Jean-Pierre Issa，医学博士，癌症表观遗传学联合项目负责人；Susan Fisher博士，人口科学副主任；Grace Ma博士，社区主任 研究)。除了扩大成员资格外，该联盟还使人们能够在以下方面获得专业知识 坦普尔大学，包括费尔斯癌症研究和分子生物学研究所，莫尔德中心 和新成立的公共卫生学院。重要的是，有了从属关系，fccc Now 极大地加强了接触寺庙周围集水区内服务不足的人口的机会 位于费城北部的大学健康科学中心。上次拨款内的其他重要成就 周期包括：a)招聘Wafik El-Deary博士担任新的翻译副主任 研究以加强基础研究成果的临床转化；b)将以下项目的直接成本增加40% 2013-2015年间资助了FCCC的研究(2770万美元至3870万美元)；c)CCSG的投资回报为43倍- 支持试点项目；d)增加治疗介入试验的应计费用，从2011年的358项增加到2014年的668项 (增加87%)；e)建立癌症表观遗传学前沿研究计划；和f) 2011-2015年发表了2200多篇论文，方案内和方案间进行了强有力的协作， 包括20%的影响因子期刊和11%的影响因子期刊。这些 积极的事态发展表明，“气候变化框架公约”的力量重新增强，其在照顾儿童方面的作用十分重要。 这一地区的癌症患者。

PROJECT SUMMARY/ABSTRACT – OVERALL The Fox Chase Cancer Center (FCCC), now in its 51st year as an NCI-designated Comprehensive Cancer Center, has undergone a profound transformation since the time of the last CCSG grant review. In 2012, Fox Chase entered into an affiliation with the Temple University Health System, creating a unique new model that combines the flexibility of a free-standing cancer center with the scientific and clinical breadth of a university- based matrix center. In addition to this organizational change, in 2013, FCCC came under new leadership with the appointment of Richard I. Fisher, MD as President and CEO of FCCC and Cancer Center Director. As a result of these developments, the size and scope of the Cancer Center have greatly expanded, both in terms of its scientific enterprise and also in the number and diversity of the patients served. Cancer-focused, Temple faculty members have been thoroughly integrated into FCCC, adding 54 new CCSG members, including three in leadership positions (Jean-Pierre Issa, MD, PhD, Co-Program Leader for Cancer Epigenetics; Susan Fisher, PhD, Associate Director for Population Science; Grace Ma, PhD, Director of Community Based Research). In addition to expanding membership, the affiliation has enabled access to specialized expertise at Temple University, including the Fels Institute for Cancer Research and Molecular Biology, the Moulder Center for Drug Discovery, and the newly created School of Public Health. Importantly, with the affiliation, FCCC now has greatly enhanced access to an underserved population within its catchment area, surrounding the Temple University Health Science Center in North Philadelphia. Other important accomplishments within the last grant cycle include: a) Recruitment of Wafik El-Deiry, MD, PhD to a new Deputy Directorship for Translational Research to enhance the clinical translation of basic research findings; b) A 40% increase in the direct costs of funded research at FCCC from 2013 - 2015 ($27.7M to $38.7M); c) 43-fold return on investment from CCSG- supported pilot projects; d) Increased accrual to treatment interventional trials, from 358 in 2011 to 668 in 2014 (an 87% increase); e) Establishment of a cutting-edge Research Program in Cancer Epigenetics; and f) Publication of more than 2,200 papers from 2011-2015, with strong intra- and inter-programmatic collaboration, including 20% in journals with Impact Factors > 8, and 11% in journals with Impact Factors > 10. These positive developments demonstrate the renewed strength of FCCC and the importance of its role in the care of cancer patients in this region.